Reducing Treatment in Metastatic Breast Cancer with a ctDNA Blood Test
In this article
Can ctDNA Help Lighten Treatment?
Many patients with ER-positive (ER+), HER2-negative metastatic breast cancer achieve long-term control with endocrine therapy (ET) and CDK4/6 inhibitors. Progression often brings chemotherapy and an increased side effect burden . Does everyone really need the same treatment intensity?
An emerging biomarker, ctDNA (circulating tumor DNA measured in blood), tracks biological tumor activity. This poster (PD7-08) summarizes ctDNA-negative patients continuing ET while delaying chemotherapy in a randomized Phase 2 trial.
Note: This is not medical advice. Treatment decisions depend on clinical status and the treating physician.
95% CI 11.8–17.2
95% CI 8.5–12.0
Hazard ratio for PFS
Poster safety summary
What Is ctDNA?
Tumor cells may release tiny DNA fragments into blood when dying or proliferating. ctDNAtesting looks for these tumor traces in a blood sample. In brief: Low/negative ctDNA may indicate biologically lower tumor burden; high/positive ctDNA may suggest more active disease.
Efficacy: Did PFS Improve?
Bars show months • Thin markers show 95% confidence intervalsHow Should This Chart Be Read?
According to the poster, median PFS of 14.5 months was longer in the de-escalation arm than the standard arm's 10.2 months. The PFS difference was presented as HR 0.65 (p=0.01). In appropriately selected patients, lighter treatment may preserve, or even extend, disease control.
Response Rate and Duration
Poster Data: Objective Response Rate (ORR) 45% vs 32%. Duration of response (DOR): 12.3 months vs 8.7 months.
Quality-of-Life Signal
The PRO summary (EORTC QLQ-C30) reported, in the de-escalation arm, a 20% reduction in fatigue and a 15% improvement in global health status . Adherence to ctDNA monitoring was 95% .
What Is ctDNA Clearance, and Why Does It Matter?
ctDNA was measured at baseline and months 3 and 6. According to the poster, the de-escalation arm had 70% ctDNA clearance . In patients without clearance, progression was high (80%), suggesting ctDNA may act as an early warning.
Subgroup Note: ESR1 Mutation
The ESR1-mutated subgroup showed a stronger PFS signal: HR 0.58. Such subgroup findings generate hypotheses and require larger-study confirmation.
Who Participated?
A randomized, multicenter Phase 2 trial included N=150 ER+/HER2− metastatic breast cancer patients. All had progression after CDK4/6 + ET . Median age: 59; 65% had visceral metastases; 40% had ESR1 mutations.
Randomization 1:1: 75 patients received ET monotherapy (AI or fulvestrant) when ctDNA-negative; the comparator was described in the poster as standard ET + chemotherapy (capecitabine or eribulin).
Did Side Effect Burden Really Fall?
The poster reported severe (Grade 3+) adverse events in 20% vs 45%. Examples: neutropenia, 5% vs 25%; nausea, 8% vs 18%; treatment discontinuation, 7% vs 15%.
ctDNA testing uses a blood sample and causes no systemic toxicity itself. Clinical risk relates mainly to misclassification and inappropriate timing.
Why Might This Not Immediately Become Routine?
This is a Phase 2 signal-generating study. Despite encouraging results, routine use generally requires (1) larger-sample Phase 3 confirmation, (2) standardization of ctDNA negativity/clearance definitions (threshold, timing), and (3) clear rules for rapid progression or visceral crisis.
Practical Message
PD7-08 suggests that, instead of identical treatment intensity for everyone , biomarkers such as ctDNA may guide who needs lighter or more intensive therapy . If Phase 3 trials confirm this, delaying chemotherapy in selected patients could reduce side effects while preserving efficacy .
Source (Poster/Abstract): André F, Bhatt NU, et al. “ctDNA-guided de-escalation in ER+/HER2− metastatic breast cancer: Phase 2 randomized trial.” Cancer Res. 2025;85(suppl 9):PD7-08.
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.